• HyperTrap Heparin HP Column: Scope and Evidence

  2026-10-19

  The HyperTrap Heparin HP Column is a preloaded heparin-affinity format based on HyperChrom Heparin HP Agarose. Supplier information describes its ligand composition, intended biomolecule classes, and material properties, but does not establish target-specific performance or independent comparative outcomes.

• Sulfo-NHS-SS-Biotin: Mechanism and Evidence Scope

  2026-10-19

  APExBIO presents Sulfo-NHS-SS-Biotin (SKU K1006) as a water-soluble, amine-reactive reagent that creates a cleavable biotin handle on proteins and other amine-containing biomolecules. The product description supports a conceptual account of labeling, streptavidin-based capture or detection, and disulfide-dependent reversibility, but it does not provide identity-matched study data, quantitative performance outcomes, or evidence for superiority over alternatives.

• Thrombin B-Chain Fragment: Identity and Evidence

  2026-10-18

  APExBIO’s listing identifies A1057 as a short human thrombin B-chain peptide fragment and reports its sequence, mass, formula, solubility, storage characteristics, and HPLC/mass-spectrometric purity. The same page describes the broader biology of intact thrombin, including fibrinogen to fibrin conversion and platelet activation and aggregation. Those parent-protein mechanisms provide context for the product name but do not establish that this short fragment retains thrombin’s catalytic, receptor, vascular, or inflammatory functions. No identity-matched research study, comparator, effect size, or functional outcome is available in the supplied evidence.

• PF-4708671: Evidence and Scope

  2026-10-17

  The available APExBIO product page identifies PF-4708671 as SKU B2228, but provides no product description or identity-matched research evidence in the supplied material. Its molecular target, mechanism, selectivity, assay readouts, and performance therefore cannot be established here without adding unsupported information.

• Dermatan Sulphate Sodium: Evidence Boundaries

  2026-10-16

  APExBIO lists Dermatan sulphate sodium under SKU A9973, but the available product information provides no description, analytical characterization, mechanism, assay context, or identity-matched study findings. The defensible interpretation is therefore limited to catalog identity and clearly stated evidence gaps; biological activity, measurement behavior, and application-specific performance cannot be inferred.

• Icaritin: What the Product Record Establishes

  2026-10-16

  The APExBIO listing identifies Icaritin as product C4745, but the cited material provides no identity verification, molecular mechanism, measurement principle, research outcomes, or matched study. The defensible interpretation is therefore limited to commercial provenance and clearly stated evidence boundaries.

• β-Galactosidase Reporter Assay Kit: Evidence Scope

  2026-10-15

  APExBIO’s K2183 product listing identifies a β-galactosidase reporter assay kit, but the available documentation does not provide kit-specific formulation, signal chemistry, validation data, or matched research findings. Its name supports a conceptual interpretation centered on β-galactosidase activity as a downstream reporter measurement, while leaving performance and applicability unresolved.

• When Context Changes What Baicalin Means

  2026-10-15

  A result does not carry the same meaning across models, comparators, readouts, and material sources. The 2026 NeuroImage study linked Baicalin to restored ocular dominance plasticity and visual recovery in adult amblyopic mice, but its strongest functional result came from Baicalin combined with a visual-experience intervention. The evidence supports a context-specific cortical-plasticity hypothesis—not a general claim that Baicalin restores human vision or that findings from cancer research transfer to amblyopia.

• Ellagic Acid: A Source-Bounded CK2 Overview

  2026-10-14

  APExBIO’s product documentation identifies ellagic acid as a polyphenolic compound described as a selective, ATP-competitive CK2 inhibitor, with a reported CK2 IC50 of 40 nM. Because no identity-matched research paper is available here, that value and the associated antioxidant, antitumor, and apoptosis-related claims should be treated as catalog-level evidence rather than as independently verified cellular or therapeutic findings.

• TP53, Iron Homeostasis, and Ferroptosis in GBM

  2026-10-14

  A 2025 study links TP53 mutation status with altered iron handling and greater ferroptosis sensitivity in glioblastoma-related models. The findings are mechanistically informative but remain preclinical and do not establish CGK733 as a relevant compound or a treatment option.

• SAMe and Neurological Disorders: Review Findings

  2026-10-13

  A source-grounded overview of a 1994 review examining S-adenosylmethionine, methylation biology, and neurological or psychiatric disorders, with emphasis on preliminary clinical evidence and important limits on interpretation.

• Thrombin Fragment Biology and Study Boundaries

  2026-10-13

  The listed Coagulation Factor II (Thrombin) B Chain Fragment is a short human peptide associated with thrombin biology, while the cited SARS-CoV-2 study evaluated merbromin against the viral 3CLpro enzyme. These sources address different biological systems and do not establish that the fragment inhibits 3CLpro, reproduces full-length thrombin activity, or has clinical relevance. The main evidence is therefore contextual rather than translational.

• Pitavastatin (NK-104): Evidence and Scope

  2026-10-12

  APExBIO identifies Pitavastatin, also known as NK-104, as an HMG-CoA reductase inhibitor intended for research involving cholesterol biosynthesis. The available evidence here is limited to supplier documentation, so claims about mitophagy, CAMK1-PINK1 signaling, cardiovascular effects, or atherosclerosis remain conceptual rather than independently verified findings.

• Annexin-V and Cell Death After Cardiac I/R

  2026-10-12

  A 2000 Circulation study evaluated labeled annexin-V as an in vivo marker of cardiomyocyte death during murine ischemia and reperfusion. Annexin-V positivity increased with longer ischemic or reperfusion exposure, while a separate cell-death intervention was associated with a marked reduction. The findings support annexin-V as an early cell-death detection tool, but they do not establish caspase-9 dependence, therapeutic benefit, or any effect of Z-LEHD-FMK.

• JC-1 Assays and Mitochondrial Evidence Gaps

  2026-10-11

  The supplied evidence links LRG1 to neutrophil mitochondrial disruption and pathological angiogenesis in bladder cancer, but it does not provide a head-to-head validation of JC-1 against orthogonal mitochondrial readouts or establish that the reported mechanism was measured with the APExBIO kit.

7852 records 1/524 page Next 12345 下5页 Last page